Chemodex

Olaparib

CHF 108.00
In stock
CDX-O0144-M100100 mgCHF 108.00
CDX-O0144-G0011 gCHF 474.00
More Information
Product Details
Synonyms AZD 2281; Ku-0059436; Lynparza; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
Product Type Chemical
Properties
Formula C24H23FN4O3
MW 434.47
CAS 763113-22-0
RTECS TH9203962
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance Off-white to beige powder.
Solubility Soluble in DMSO (20mg/ml) or DMF (10mg/ml). Slightly soluble in ethanol (1mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key FDLYAMZZIXQODN-UHFFFAOYSA-N
Smiles O=C(C1CC1)N2CCN(C(C3=C(F)C=CC(CC(C4=C5C=CC=C4)=NNC5=O)=C3)=O)CC2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Olaparib is a cell-permable potent inhibitor of PARP1 and PARP2 (IC50=5 and 1nM, respectively) but is less effective against the PARP tankyrase-1 (IC50=1.5μM). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in base excision repair (BER), counteracting against DNA alkylating agents. Olaparib is a anticancer and chemotherapeutic agent (especially in cancers with BRCA mutations) that can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.

Product References

(1) K.A. Menear, et al.; J. Med. Chem. 51, 6581 (2008) | (2) S. Rottenberg, et al.; PNAS 105, 17079 (2008) | (3) B.P. Rowe & P.M. Glazer; Breast Cancer Res. 12, 1 (2010) | (4) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (5) R. Plummer; Breast Cancer Res. 13, 1 (2011) | (6) M. Javle & N.J. Curtin; Ther. Adv. Med. Oncol. 3, 257 (2011) | (7) D. Davar, et al.; Curr. Med. Chem. 19, 3907 (2012) | (8) C.C. Gunderson & K.N. Moore; Future Oncol. 11, 747 (2015) | (9) F. De Felice, et al.; Drug Des. Devel. Ther. 11, 547 (2017) | (10) J. Stewart, et al.; Expert Rev. Anticancer Ther. 18, 947 (2018)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.